A B S T R A C T The effects of somatostatin and epinephrine have been studied with regard to glucoseinduced insulin release and 45Ca++ uptake by rat pancreatic islets after 2 days in tissue culture and with regard to 45Ca++ efflux from islets loaded with the radioisotope during the 2 days of culture. 45Ca++ uptake, measured simultaneously with insulin release, was linear with time for 5 min. 45Ca++ efflux and insulin release were also measured simultaneously from perifused islets.
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Glucose (16.7 mM) markedly stimulated insulin release and 45Ca++ uptake. Somatostatin inhibited the stimulation of insulin release by glucose in a concentration-related manner (1-1,000 nglml) but was without effect on the glucose-induced stimulation of 45Ca++ uptake. Similarly, under perifusion conditions, both phases of insulin release were inhibited by somatostatin while no effect was observed on the pattern of 45Ca++ efflux after glucose.
Epinephrine, in contrast to somatostatin, caused a concentration-dependent inhibition of the stimulation of both insulin release and 45Ca++ uptake by glucose. Both phases of insulin release were inhibited by epinephrine and marked inhibition could be observed with no change in the characteristic glucose-evoked pattern of 45Ca++ efflux (e.g., with 10 nM epinephrine). The inhibitory effect of epinephrine on 45Ca++ uptake and insulin release appeared to be mediated via an a-adrenergic mechanism, since is was abolished in the presence of phentolamine.
Somatostatin inhibits insulin release without any detectable effect upon the handling of calcium by the islets. In contrast, inhibition of insulin release by epinephrine is accompanied by a partial inhibition of glucose-induced Ca++ uptake.
INTRODUCTION
Somatostatin (1) (2) (3) (4) (5) (6) and epinephrine (7) (8) (9) (10) (11) (12) inhibit the stimulation of insulin release by a variety of agents, including sugars, amino acids, and activators of the adenylate cyclase-cyclic AMP system. In searching for the mode of inhibition it has been suggested that they interfere with calcium handling by the pancreatic B cells. Thus, Curry and Bennett showed that the inhibitory effect of somatostatin on glucose-stimulated insulin release from the perfused rat pancreas was attenuated when the calcium concentration in the medium was increased (13, 14) . These results, and others (15, 16) , suggested a connection between somatostatin and calcium, either by somatostatin inhibition of calcium uptake, or by calcium interference with somatostatin receptor-binding or action. Malaisse-Lagae and Malaisse showed epinephrine to inhibit glucose-stimulated net uptake of 45Ca++ by isolated islets when measured after 90 min of incubation (17) . Brisson and Malaisse later reported that epinephrine increased the outward flux of 45Ca++ from preloaded islets and postulated that the inhibitory effect on insulin release might be via lowering of the cytosolic Ca++ concentration (18) . These studies on calcium uptake and efflux were, however, performed in the presence of very high epinephrine concentrations (10-100 ,uM). As epinephrine inhibits insulin release at much lower concentrations, it seemed necessary to reexamine the effect of epinephrine on calcium fluxes in islets. In view of the few reports on the effect of somatostatin on calcium handling, it seemed of particular interest also to study its effect on calcium uptake and efflux.
In the study reported here, collagenase-isolated islets were used after a maintenance period of 2 ineffective on freshly isolated islets (4, 19, 20) , whereas the sensitivity is increased after a period of culture (21 (23, 24) . The tubes were incubated in a water bath at 37°C without shaking. The incubation was stopped and the islets were separated from the incubation buffer (usually after 5 min of incubation) by centrifugation for 15 s at 8,000 g in a Greiner microfuge (type 2F1). By this procedure (25) (26) (27) (28) ) the islets were effectively separated from the buffer by passage through the phthalate mixture and into the urea layer. Insulin release by the islets was assayed on an aliquot of the supematant buffer. The bottoms ofthe tubes were cut above the urea layer and placed in 5 ml Instagel for liquid scintillation spectrometry. In every experiment blanks containing cut microfuge tubes without IAbbreviations used in this paper: IRI, immunoreactive insulin; KRB buffer, Krebs-Ringer bicarbonate buffer.
islets, standards of the radioactive medium (20 ,ul) , and samples containing 45Ca++ only for the estimation of spillover of 45Ca++ counts into the 3H channel were added for spectrometry. Blanks without islets did not differ from the background counts. Ca++ uptake was calculated from the 45Ca++ space in excess of the [3H]sucrose space. The sucrose space became maximal within 1 min of incubation and remained constant over 30 min. At 5 min the extracellular space was 1.22±0.10 nl/islets (n = 15) (mean±SEM) in the presence of 2.8 mM glucose and 1.25±0.11 nl/islet (n = 14) in the presence of 16 .7 mM glucose.
The insulin release determined on the same islets as the Ca++ uptake, was corrected to indicate the true release over the 5-min incubation period by subtraction of the values measured at zero time. Immunoreactive insulin (IRI) was measured by the method of Herbert et al. (2.9) with rat insulin as standard. Neither epinephrine nor somatostatin interfered with the immunoassay at the concentrations employed.
Perifusion system and measurement of 45Ca++ efflux. For the measurement of 45Ca++ efflux, islets that had been preloaded during 45-47 h with 45CaCl, were perifused using 40 islets per chamber. The perifusion system has been described in detail elsewhere (30, 31) , but the following modifications were made: the volume of the chamber was decreased to 70 pul and two rotating oxygen distributors also serving as medium reservoirs were connected to each chamber. The dead space of the system was approximately 1.4 ml and the flow rate was 1.4 ml/min. The perifusate consisted of KRB buffer containing 2.5 mM CaCl2, 0.5% dialyzed bovine serum albumin, and 2.8 mM glucose. The islets were placed directly in the perifusion chamber without washing. From 
RESULTS
Time course of 45Ca++ uptake and insulin release. 45Ca++ uptake and insulin release were measured in the presence of either 2.8 or 16.7 mM glucose over different time periods between 0 and 30 min. As is shown in Fig. 1 45Ca++ uptake by the islets was biphasic. At both glucose concentrations an initial rapid phase, which was linear with time for 5 min, was followed by a phase with a lower rate of 45Ca++ uptake. The uptake was stimulated by high glucose relative to low glucose at 1 min (P < 0.02) and at all subsequent time points. Insulin was released at a low basal rate in the presence of 2.8 mM glucose. The release rate was markedly stimulated by 16 .7 mM glucose resulting in significantly stimulated cumulative insulin release at 2 min (P < 0.005) and thereafter. The sigmoidal pattern of insulin release in the presence of high glucose in this incubation system is explained by the biphasic release of insulin seen in the dynamic system (compare Fig. 3 ).
Since 45Ca++ uptake was linear with time over the initial 5 min of incubation, subsequent measurements of Ca++ uptake were performed over 5 min only.
Effect of somatostatin on 45Ca++ uptake and insulin release. As already observed 16 a large increase in IRI release relative to 2.8 mM glucose when measured over the 5-min incubation period (Fig. 2) . Somatostatin was tested at concentrations between 1 and 1,000 nglml (0.54 nM to 0.54 ,uM) in the presence of 16.7 mM glucose. All somatostatin concentrations used significantly inhibited IRI release. The inhibition was 36, 45, 72, and 73% with 1, 10, 100, and 1,000 ng/ml somatostatin, respectively. The change of glucose from 2.8 to 16.7 mM was associated with a doubling in 45Ca++ uptake. Strikingly, somatostatin was without effect on 45Ca++ uptake, even at the highest concentration of 1,000 ng/ml.
Effect of somatostatin on 45Ca++ efflux and insulin release. Two concentrations of somatostatin 100 and 1,000 ng/ml were employed. The results ofexperiments with 1,000 ng/ml are shown in Fig. 3 (Fig. 3) . Similar results were obtained when 100 ng/ml of somatostatin was used. First phase insulin release was inhibited by 37% and second phase by 43% in the absence of any change in the characteristic 45Ca++ efflux pattern. Effects of epinephrine on 45Ca++ uptake and insulin release. The effects of 16.7 mM glucose and four concentrations of epinephrine on 45Ca++ uptake and insulin release were studied. In Fig. 4 are shown the results when 0.1 and 10 nM, 1 ,uM, and 0.1 mM epinephrine were employed. 16 .7 mM glucose stimulated insulin release fourfold relative to 2.8 mM glucose.
The glucose-stimulated insulin release was inhibited by epinephrine in a dose-related manner by 39, 52 , 112, and 113% with 0.1 and 10 nM, 1 ,uM, and 0.1 mM epinephrine, respectively.
It is also shown in Fig. 4 that 16.7 mM glucose caused the expected increase of 45Ca++ uptake. Epinephrine at 0.1 nM decreased 45Ca++ uptake but the inhibition was not statistically significant. 10 nM, 1 AM, and 0.1 mM epinephrine all significantly inhibited Ca++ uptake.
The a-adrenergic blocking agent, phentolamine, was used to examine the nature of the inhibitory effect of epinephrine on 45Ca++ uptake. As shown in Table I Somatostatin, Epinephrine, Insulin Release, and 45Ca++ Fluxes 1 mM. In this case both phases of insulin release were abolished, as expected. 1 mM epinephrine inhibited 45Ca++ efflux by 83% during the first 5 min after the addition of high glucose and by 53% subsequently (Fig. 6) . DISCUSSION Insulin release. The biphasic insulin release induced by 16.7 mM glucose is similar to that observed in the perfused pancreas with a rapid first phase, a clearly distinguishable nadir, and a slowly increasing second phase reaching about the same level of secretion rate as the first phase. The perifusion of isolated islets maintained under tissue culture conditions for 2 days therefore appears well suited for studies on insulin release. 45Ca++ uptake and efflux. The method of measuring 45Ca++ uptake used in this study has been used previously for other tissues (25) (26) (27) and islets (28, 32) but has been modified to allow the simultaneous measurement of insulin release. As 45Ca++ uptake was linear with time for 5 min, all experiments were performed over this period. Measurement of 45Ca++ uptake over longer periods was not studied because without linearity the 45Ca++ in the islet can no longer be interpreted solely in terms of uptake. It is clear that glucose caused a prompt and marked increase in the rate of 45Ca++ uptake and insulin release. The values of uptake reported here are somewhat less than those reported for the larger islet from the ob-ob mouse (33, 34) .
In previous studies on 45Ca++ efflux from rat islets, the islets were loaded with 45Ca++ for either 60 (35, 18) or 90 min (36) . The pattern of 45Ca++ efflux in response to glucose in these three studies was an initial inhibition of 45Ca++ followed by a stimulation of efflux. In our studies with islets loaded with 45Ca++ during 2 days in culture conditions and perifused in a micro (70-,l) perifusion chamber, the effect of glucose to inhibit 45Ca++ efflux is not seen. Only the stimulation of 45Ca++ efflux is observed. In other experiments to be reported elsewhere2 the inhibitory effect of glucose on 45Ca++ efflux was detected in the 2-day loaded islets by the device of lowering the external Ca++ concentration. Thus, the inhibitory effect of glucose on 45Ca++ efflux is operative but is probably obscured by the rapidity of the effect of glucose to also stimulate 45Ca++ efflux. In fact, in the results reported here, the stimulation of 45Ca++ efflux peaks within 3 min of exposure to glucose, i.e., at a time when the inhibitory effect reported by others (35, 36) has not reached the nadir of the initial decrease of 45Ca++ efflux. Effect of somatostatin. Somatostatin inhibited glucose-stimulated insulin release in a dose-related fashion. The first phase insulin release measured over 5 min in the static system showed a similar sensitivity to somatostatin, as has been reported for the perfused pancreas (1, 2, 19) for monolayer cultures of the endocrine pancreas (3) and for isolated islets after 2 days in culture (21) . When high concentrations of somatostatin were used (100 and 1,000 ng/ml) both phases of insulin release measured in the dynamic system were inhibited to a similar extent. Despite potent inhibition of insulin release, no effect of somatostatin on glucosestimulated 45Ca++ uptake or 45Ca++ efflux could be detected. The present results appear to conflict with the recent reports by Oliver (37) and by Bhathena et al. (15) who observed an inhibition of glucose-stimulated retention of 45Ca++ by 1,000 and 2,000 ng/ml somatostatin, respectively. The experimental conditions differed, however, in that the 45Ca++ retained by the islets after 60 or 90 min incubation was measured rather than the rate ofCa++ uptake. Thus, the observed inhibition might be indirect or secondary to the action of somatostatin to decrease insulin release perhaps by influencing metabolism. For instance, somatostatin has recently been reported to inhibit glucose metabolism by isolated islets (6) and Sener et al. have shown that 45Ca++ net uptake is proportional to glycolysis (38) . The present study does not offer an explanation for the reported effects of calcium to attenuate the inhibitory action of somatostatin (13) (14) (15) (16) .
Effect of epinephrine. In the present study 0.1 nM epinephrine, a concentration approximating plasma levels in resting man (39) , was the threshold concentration for inhibition of glucose-stimulated insulin release. The inhibition by 0.1 nM epinephrine was associated with a small, but nonsignificant, decrease in Ca++ uptake. Higher concentrations of epinephrine inhibited both release and Ca++ uptake. Like the effect of epinephrine to inhibit insulin release (40) (41) (42) (43) (44) , the inhibition of 45Ca++ uptake appears to be mediated by a-adrenergic mechanisms. It is of interest to note that when the insulin release in response to high glucose was abolished in the presence of 1 (53) , inhibit glucose-induced insulin release. Since somatostatin, as well as epinephrine, inhibits insulin release stimulated by a variety of substances, it appears natural to focus on a site in the release mechanism common to many secretagogues when looking for the mode of action of the two inhibitors. The data presented here exclude an action of somatostatin on the Ca++ uptake mechanism of the islets. Somatostatin clearly caused a potent inhibition of insulin release without affecting either the influx or efflux of 45Ca++. Epinephrine, on the other hand, did inhibit glucose-stimulated 45Ca++ uptake and this could indicate a possible mode of action of this hormone (17) as could the inhibition of adenylate cyclase (54) (55) (56) and the lowering of islet cyclic AMP levels (57, 58) . The latter seems unlikely since epinephrine inhibits insulin release even in the presence of dibutyryl cyclic AMP (9). Efendic et al. (59) , measuring [3H]cyclic AMP formation in freshly isolated islets, could not observe an effect of high somatostatin concentrations on islet cyclic AMP content, but in one condition cyclic AMP release into the medium was inhibited.
It has been suggested that at least part of the increase in 45Ca++ efflux caused by high glucose concentrations is associated with insulin release and might be released together with the secretory granules (35) . In the present study, a striking dissociation between insulin release and 45Ca++ efflux was observed in that both somatostatin and epinephrine inhibited insulin release without affecting 45Ca++ efflux. Thus, epinephrine at 1 ,uM abolished glucose-stimulated insulin release, while 45Ca++ efflux was not significantly altered. It is clear, therefore, that the contribution of 45Ca++ in the insulin containing granules to 45Ca++ efflux after glucose stimulation is insignificantly small.
In conclusion, epinephrine could exert at least some of its inhibitory effect upon insulin release by inhibition of calcium uptake, whereas somatostatin is inhibitory to insulin release by a mechanism which does not affect glucose-induced changes in calcium fluxes.
